Form DEF 14A RIGEL PHARMACEUTICALS For: 3 April
#Rigel Pharmaceuticals #DEF 14A #proxy statement #annual meeting #shareholder vote #executive compensation #director elections
📌 Key Takeaways
- Rigel Pharmaceuticals filed its definitive proxy statement (DEF 14A) on April 3.
- The filing outlines matters for shareholder vote at the upcoming annual meeting.
- It includes details on director elections, executive compensation, and other corporate governance items.
- Shareholders are provided with information to make informed voting decisions.
🏷️ Themes
Corporate Governance, Shareholder Voting
Entity Intersection Graph
No entity connections available yet for this article.